Haematoxylin

Haematoxylin

SCHEMBL30101752

Oc1cc2c(cc1O)C1c3ccc(O)c(O)c3OCC1(O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
KDM4E B2RXH2 4/20 1.00
HPGD P15428 4/20 1.00
MAPK1 P28482 4/20 1.00
RECQL P46063 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
ALDH1A1 P00352 3/20 1.00
CYP3A4 P08684 3/20 1.00
HSD17B10 Q99714 3/20 1.00
MET P08581 3/20 1.00
KIT P10721 3/20 1.00
FGFR1 P11362 3/20 1.00
SRC P12931 3/20 1.00
KDR P35968 3/20 1.00
G6PD P11413 2/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
MEN1 O00255 2/20 1.00
ALOX15 P16050 2/20 1.00
KMT2A Q03164 2/20 1.00
NSD2 O96028 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hematoxylin SCHEMBL29363003 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL30089789 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL29366910 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL1784957 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL29360033 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL7026124 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL29357236 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL19654 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL1747 1.00 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL19816198 0.99 MAPT (0.97) MAPTKDM4EHPGDMAPK1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3636600-B1 A SORPTION COMPOSITION FOR COMPLEX WATER PURIFICATION EWI BVBA (BE) 2022-11-30 EP claimed
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY NEW YORK UNIVERSITY (US) 2025-07-03 US disclosed
US-12228481-B2 Expansion microscopy compatible anchorable HandE staining for histopathology EXPANSION TECHNOLOGIES (US) 2025-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY DCLRE1B, RNASE1, ADAR MAPT 4087/4885KDM4E 4082/4885HPGD 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.